Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Tumor, Solid: early-phase trial registry
7 of 12 indexed Tumor, Solid trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 7 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Tumor, Solid: 12 US clinical trials tracked, 7 recruiting.
Tumor, Solid is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Aadi Bioscience, running 2 of these trials.
Enrollment posture brief
Registry condition tumor-solid
OPEN 7 | RECR 58% | LATE 0 | EARLY 9 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Anterior Cruciate Ligament Reconstruction (58% recruiting · 12 trials)
Tumor, Solid lists 7 open slots (58% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Tumor, Solid on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Tumor, Solid is recruiting above its size-band peers.
7 of 12 indexed trials (58.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Tumor, Solid research.
Aadi Bioscience accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Tumor, Solid trials plan to enrol fewer than 100 people.
Median target enrolment is 78 among the 12 trials that report a genuine target (sentinel values excluded). 8 of those (66.7%) plan for fewer than 100 participants.
-
Tumor, Solid research is mostly interventional.
10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Immune Profiling for Cancer Immunotherapy Response
Dartmouth-Hitchcock Medical Center
NCT06116032
TumorGlow Intraoperative Molecular Imaging (IMI)
University of Pennsylvania
NCT04723810
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse
NCT06090266
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics
NCT05378425
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Shenzhen Ionova Life Sciences Co.
NCT04443088
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
NCT03454035
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Aadi Bioscience
NCT05661461
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience
NCT05103358
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
HistoSonics
NCT05820087
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
Eikon Therapeutics
NCT04196530
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
MiNK Therapeutics
NCT05108623
Tumor Rebiopsy in Children and Adolescents With Recurrent or Progressive Solid Malignancies
St. Jude Children's Research Hospital
NCT03276702
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Tumor, Solid records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Tumor, Solid trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Tumor, Solid page
12 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Tumor, Solid trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Aadi Bioscience sponsors the most Tumor, Solid trials on record, review their full trial history before evaluating a specific study. See Aadi Bioscience's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tumor, Solid condition card totals 12 registered trials; most-linked intervention nab-sirolimus; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.